Study results presented today demonstrate that the oral, once-daily treatment regimen of glecaprevir/pibrentasvir resulted in 95 percent sustained virologic response rates 12 weeks post treatment in patients with HCV genotype 3. In the ENDURANCE-3 study, presented at The International Liver Congress™ 2017 in Amsterdam, The Netherlands, patients infected with HCV genotype 3 without cirrhosis and who had no previous treatment history were treated with the new regimen for eight or 12 weeks, which was well tolerated.

This post comes from the RSS feed of EurekaAlert, you can find more here!

Written by admin